Is Compounded Semaglutide Still Available in 2026? The FDA 503B Update Explained

Yes, compounded semaglutide and tirzepatide remain available through 503A patient-specific compounding pharmacies in 2026. On April 30, 2026, the FDA proposed not to include semaglutide, tirzepatide, and liraglutide on the 503B Bulks List — a proposal that affects large-scale outsourcing facilities only. The public comment period closes June 30, 2026, and no final rule has been issued. 503A compounding — the pathway AHC uses — operates under separate legal authority and is not affected by this proposal. AHC’s program continues uninterrupted.

Is compounded semaglutide still available in 2026? If you are a current AHC patient or are considering starting a GLP-1 program, this is the question you need answered — clearly and without the regulatory jargon that makes most explanations confusing.

This guide explains exactly what the FDA proposed on April 30, 2026, what the difference between 503A and 503B compounding actually means for your medication access, what AHC’s current status is, and what happens next.

What the FDA Actually Proposed on April 30, 2026

On April 30, 2026, the FDA published a notice in the Federal Register (Docket 2026-08552) proposing not to include semaglutide, tirzepatide, and liraglutide on the 503B Bulks List. The comment period closes June 30, 2026, and no final rule has been issued.

To understand what this means, you need to understand what the 503B Bulks List is — and what it is not.

The 503A vs 503B Distinction: Why This Matters for Your Medication

AHC’s compounding pharmacy partners operate under 503A authority. Every prescription is written for a specific named patient following a physician evaluation. The FDA’s April 30 proposal targets 503B outsourcing facilities — large-scale compounders that produce medications in bulk without patient-specific prescriptions. The 503A pathway that AHC uses is governed by separate sections of the FD&C Act and is not within the scope of the April 30 proposal.

Why the FDA Made This Proposal

The FDA’s stated rationale in the Federal Register notice is that semaglutide and tirzepatide no longer meet the 503B inclusion criteria because:

• The shortage status for both medications has been resolved — FDA removed semaglutide from its shortage list in February 2026 and tirzepatide shortage conditions also stabilized.
• 503B compounding is permitted when there is a ‘clinical need’ that FDA-approved products cannot meet. The FDA determined that for semaglutide and tirzepatide, FDA-approved products (Wegovy, Ozempic, Mounjaro, Zepbound) are available and accessible.
• The FDA explicitly noted that affordability and insurance access do not constitute ‘clinical need’ under its interpretation of the 503B statute — a decision that has generated significant industry pushback in the comment process.

What Has NOT Changed

• 503A patient-specific compounding of semaglutide and tirzepatide remains legal and continues under existing state pharmacy board oversight.
• Patients with valid prescriptions from licensed physicians can continue to access compounded semaglutide and tirzepatide through licensed 503A pharmacies.
• No final rule has been issued — the current FDA action is a proposed rule open for public comment through June 30, 2026.
• AHC’s licensed physician evaluation, prescription, and dispensing process through 503A partner pharmacies continues uninterrupted.

What Could Change After June 30, 2026

After the comment period closes, the FDA will review all submitted comments and issue a final determination. Several outcomes are possible:

• The proposal could be adopted as written, which would restrict 503B outsourcing facility production while leaving 503A unaffected.
• The proposal could be modified in response to industry and patient advocacy comments — 373 comments had already been submitted as of mid-May 2026.
• Congressional action: several bills have been introduced seeking to define affordability and access as legitimate clinical need criteria for 503B compounding.

The 503A pathway — through which AHC operates — is not within the scope of the proposed rule and would not be affected by the final determination on the 503B Bulks List even if the proposal is adopted exactly as written.

How to Spot Misleading Information About This Proposal

Some sources are conflating the 503B proposal with a complete ban on compounded GLP-1 medications. This is factually incorrect. The proposal specifically targets 503B outsourcing facilities only. Providers claiming their programs are ‘shutting down’ due to this proposal are either describing 503B-dependent operations or overstating the regulatory impact on 503A programs. AHC’s 503A-based program is not affected.

AHC’s Current Program Status

AHC’s compounded semaglutide and tirzepatide programs through licensed 503A pharmacy partners continue without interruption. Compounded semaglutide is available at $129/month through AHC’s program. Compounded tirzepatide is available at $169/month through AHC’s program. Both programs include physician evaluation, ongoing provider access, and flat-rate pricing at every dose tier with no membership fees.

Frequently Asked Questions

1. Is compounded semaglutide still available in 2026?

Yes. Compounded semaglutide remains available through licensed 503A patient-specific compounding pharmacies. The FDA’s April 30, 2026 proposal specifically targets 503B outsourcing facilities and does not affect 503A compounding. AHC’s program, which operates through 503A partner pharmacies with patient-specific prescriptions, continues uninterrupted.

2. What is the FDA 503B semaglutide proposal?

On April 30, 2026, the FDA proposed not to include semaglutide, tirzepatide, and liraglutide on the 503B Bulks List — the list that allows large-scale outsourcing facilities to compound these medications in bulk without patient-specific prescriptions. The public comment period closes June 30, 2026. No final rule has been issued.

3. Does the FDA proposal affect AHC’s compounded semaglutide program?

No. AHC operates through 503A patient-specific compounding pharmacies, not 503B outsourcing facilities. The FDA’s April 30 proposal only addresses 503B facilities. 503A compounding operates under separate legal authority and is not within the scope of this proposal.

4. What is the difference between 503A and 503B compounding?

503A compounding pharmacies prepare medications for specific named patients under individual prescriptions from licensed physicians. 503B outsourcing facilities produce medications in bulk quantities without patient-specific prescriptions for distribution to hospitals, clinics, and distributors. AHC’s pharmacy partners are 503A operations.

5. Should I start GLP-1 therapy now given the regulatory uncertainty?

Yes, if you are eligible. 503A patient-specific compounding remains legal and AHC’s program continues without disruption. The FDA’s proposal does not create any current limitation on accessing compounded semaglutide or tirzepatide through 503A providers like AHC.

AHC’s Program Continues — Start Your Evaluation Today

AHC operates through licensed 503A pharmacy partners with valid physician prescriptions for every patient. Compounded semaglutide from $129/month. Compounded tirzepatide from $169/month. Begin your evaluation. For patient support questions, visit alternatehealthclub.com/faqs/.

Medical Disclaimer: Compounded semaglutide and tirzepatide are not FDA-approved and have not been evaluated for safety, efficacy, or quality by the FDA. All clinical services are provided by independently contracted, U.S.-licensed clinicians. Individual results vary. This content is for informational purposes only and does not constitute medical advice.